Mometasona Teva (Mometasone Furoate)

Mometasone furoate penetrates nasal epithelial cells and binds to glucocorticoid receptors. The drug‑receptor complex alters gene transcription, suppressing pro‑inflammatory cytokines and mediators. This leads to decreased vascular permeability, reduced edema, and inhibition of inflammatory cell recruitment, providing relief from nasal symptoms.

The specific dose and frequency of Mometasona Teva are determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label without making any changes on their own.

Safety data for mometasone furoate nasal use in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasona Teva (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with lower‑potency agents such as fluticasone or budesonide, mometasone often provides comparable symptom control with once‑daily dosing, but selection should be individualized based on patient response and physician preference.

Store Mometasona Teva at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Do not freeze. Keep the nasal spray cap tightly closed when not in use to maintain sterility.

Mometasona Teva is a nasal spray. The prescribed number of sprays is delivered into each nostril, typically once daily, unless otherwise directed by a healthcare professional. Patients should avoid blowing the nose immediately after administration and should follow the device’s instructions for proper technique.

Serious but rare risks include severe nosebleeds, perforation of the nasal septum, adrenal suppression with prolonged high‑dose use, opportunistic fungal infections of the nasal cavity, and systemic allergic reactions such as anaphylaxis. Patients should seek medical attention if they experience unusual bleeding, persistent pain, or signs of infection.

Mometasona Teva should be avoided in individuals with known hypersensitivity to mometasone furoate or any excipients in the formulation. It is also contraindicated in patients with active, untreated nasal infections or in those for whom corticosteroid therapy is medically inadvisable without prior physician evaluation.